CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: December 22, 2020
Result type: Reports
Project Number: SR0652-000
Product Line: Reimbursement Review

Generic Name: ozanimod

Brand Name: Zeposia

Manufacturer: Celgene Inc.

Therapeutic Area: Multiple Sclerosis, relapsing - remitting

Indications: For the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to decrease the frequency of clinical exacerbations.

Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS).

Submission Type: Initial

NOC Status at Filing: Pre NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openJuly 27, 2020
Call for patient input closedSeptember 16, 2020

- Patient input submission received from MS Society of Canada

Submission receivedAugust 25, 2020
Submission acceptedSeptember 09, 2020
Review initiatedSeptember 14, 2020
Draft CADTH review report(s) provided to sponsor for commentDecember 01, 2020
Deadline for sponsors commentsDecember 10, 2020
CADTH responses on draft review report(s) provided to sponsorJanuary 08, 2021
Expert committee meeting (initial)January 20, 2021
Draft recommendation issued to sponsorFebruary 03, 2021
End of embargo periodMarch 18, 2021

- Request for extension to feedback period received from the sponsor

- Feedback extension request granted

- Reconsideration requested

- Target EXPERT COMMITTEE reconsideration meeting date to be determined